(Date:1/7/2009)... Jan. 7 Stryker Corporat...articipate in the following investor,conference: ...Pacific Time, 27th Annual J.P. Morgan ...California, , A simultaneous webcast of ...tryker,s website at www.stryker.com via the For ...
(Date:1/7/2009)...outhwest; lowest rates in Northeast, government re...ews) -- The teen birth rate in the United States i...ing almost every region of the country, according ... 2007, the U.S. Centers for Disease Control and Pr... entire nation had increased for the first time in...
(Date:1/7/2009)..., Jan. 7 BrainLAB, Inc., a leader ...asive medical treatments,announces a new, custom...usiness in consideration of continued growth and a...ating field sales and support structures, customer... focused organization. Streamlined,responsibiliti...
(Date:1/7/2009)...J., Jan. 7 Seabrook Hou...ent center, is pleased to announce its plans for e...following is just a few of the ways Seabrook Hou...iction is possible and that treatment works. Seabr...r every family who needs it and to educate the pub...
Breaking Medicine News(10 mins):Health News:Stryker To Present at Investor Conference 2Health News:Teen Birth Rate Up in 26 States in 2006 2Health News:BrainLAB, Inc. Announces New, Streamlined Surgery Business Division 2Health News:Seabrook House Embraces the New Year with New Programs 2Health News:Seabrook House Embraces the New Year with New Programs 3...e to reduced number of sperm donors nationally, th...spital has been forced to say ‘no’ to its new pati...nt at Scotland has been plunged into crisis becaus...nts treated halfway may need to register in next c...
...cording to a Canadian National research project ch...als hazardous to health which are PCBs to flame re...l Defence, points out those certain cases has chil...s than their parents. On an average 23 known or su...
...inagar, June 4. Nearly Rs 3.66 crore has been sanc...3 Aanganwari centres in Jammu and Kashmir's Doda d...e Minister Haji Nisar Ali said today. A total of 1...l in the district while 693 more are being set up ...
...w York, - A study aimed at gauging adolescent heal...and virginity till marriage, show a propensity to ... to teens who are not so rigid about maintaining t...rginity vows and sexual encounters among students ...
Other Medicine News:(Date:12/17/2008)...ANCISCO, Dec. 17 Medivat...it has completed patient enrollment in a,Phase 1-...ovel androgen,receptor antagonist, in castration-...ill seek approval from the U.S. Food and Drug Admi...rials next year. , The open-label, U.S. Pha...
(Date:12/17/2008)...ILLE, Calif., Dec. 17 Ne...: NTII ) today announced that an independent,Da...hat the current clinical,trials of Viprinex(TM) f...kely,to show benefit. As a result, the company ha...I will obtain and analyze the data before evaluati...
(Date:12/16/2008)...DA, Md., Dec. 16 Public...on reducing colon cancer deaths suggests a lower i...cian experts from the American College of Gastroen... that even if the assumptions and design of this c...onoscopy remains the best available option for det...
(Date:12/15/2008)...roadcast on December 18, 2008 at 9 a.m. Eastern Ti...re-FirstCall/ -- MannKind Corporation (Nasdaq: ...ical results from its final two Phase 3 studies of...aled insulin product, at 9 a.m. Eastern Time on Th...pate in the live call by telephone, please dial (8...
Breaking Medicine Technology:Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 2Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 3Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients 4Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis 2Quality Colonoscopy Exam Remains Best Strategy for Detection of Polyps and Cancers According to Experts From the American College of Gastroenterology 2MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes 2MedApps Wins Nokia 2008 Mobile Rules 21 Business Plan Competition Award 14870 1MedApps Wins Nokia 2008 Mobile Rules 21 Business Plan Competition Award 14870 2MedApps Wins Nokia 2008 Mobile Rules 21 Business Plan Competition Award 14870 3Plant gene clusters for natural products 2577 1Plant gene clusters for natural products 2577 2Iowa State researchers developing system to efficiently convert biomass to ethanol 4128 1Iowa State researchers developing system to efficiently convert biomass to ethanol 4128 2Iowa State researchers developing system to efficiently convert biomass to ethanol 4128 3ImaRx to Report Corporate Updates and 4Q07 Financial Results 4126 1ImaRx to Report Corporate Updates and 4Q07 Financial Results 4126 2...4, 2007 /PRNewswire-FirstCall/ --,Bionovo, Inc.,s ...2,results for the treatment of hot flashes associa...n were enrolled in the company,s,double-blind, pla...nopausal women with 50 or more moderate to severe ...ee treatment groups receiving,MF101 (5 grams/day),...
... 2007 /PRNewswire-FirstCall/ -- VION,PHARMACEUTICA...cal,data in a poster session at the 43rd Annual Me... (ASCO) on its lead anticancer agent,Cloretazine(R...l in,patients with relapsed or refractory small ce...retazine(R) (VNP40101M) in two,separate subpopulat...
Other Medicine Technology:Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 2Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 3Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 4Bionovo's MF101 Shows Positive Safety, Tolerability and Efficacy in,Phase 2 Trial 5Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 2Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 3Vion Pharmaceuticals Presents Updated Clinical Data from a Phase II,trial of Cloretazine (VNP40101M) in Patients with Relapsed or,Refractory Small Cell Lung Cancer 4...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: